PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer
Author:
Affiliation:
1. Pathology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
2. Hematology & Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
Publisher
Future Medicine Ltd
Subject
Biochemistry, medical,Clinical Biochemistry,Drug Discovery
Link
https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2019-0344
Reference12 articles.
1. Metastatic and triple-negative breast cancer: challenges and treatment options
2. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
3. PD-1 and Its Ligands in Tolerance and Immunity
4. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells;Pharmaceutics;2022-10-18
2. Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC);Pharmaceuticals;2022-04-27
3. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis;Frontiers in Immunology;2021-04-21
4. GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer;Biomedicines;2021-04-01
5. Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review;Cancer Management and Research;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3